JPMorgan Chase & Co. Issues Pessimistic Forecast for Cooper Companies (NASDAQ:COO) Stock Price

Cooper Companies (NASDAQ:COO) had its target price lowered by JPMorgan Chase & Co. from $120.00 to $110.00 in a research note published on Friday morning,Benzinga reports. The firm currently has an overweight rating on the medical device company’s stock.

Several other analysts have also weighed in on COO. StockNews.com lowered Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research note on Friday. Citigroup lowered their price objective on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a research report on Friday. Morgan Stanley cut their target price on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research report on Friday, December 6th. Finally, Wells Fargo & Company boosted their target price on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Cooper Companies has an average rating of “Moderate Buy” and a consensus price target of $111.89.

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $85.00 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The company has a market cap of $16.96 billion, a PE ratio of 43.59, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. The company has a 50 day moving average of $92.38 and a 200-day moving average of $99.44. Cooper Companies has a 1-year low of $82.61 and a 1-year high of $112.38.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. The firm had revenue of $964.70 million during the quarter, compared to analysts’ expectations of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. As a group, equities research analysts forecast that Cooper Companies will post 3.98 earnings per share for the current fiscal year.

Institutional Trading of Cooper Companies

Institutional investors have recently modified their holdings of the business. State Street Corp grew its position in shares of Cooper Companies by 1.2% in the 3rd quarter. State Street Corp now owns 8,590,689 shares of the medical device company’s stock valued at $947,897,000 after buying an additional 104,521 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Cooper Companies by 2.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,678,965 shares of the medical device company’s stock worth $705,928,000 after acquiring an additional 155,233 shares during the period. JPMorgan Chase & Co. boosted its holdings in Cooper Companies by 1.5% in the fourth quarter. JPMorgan Chase & Co. now owns 5,004,523 shares of the medical device company’s stock valued at $460,066,000 after acquiring an additional 74,501 shares during the last quarter. Geode Capital Management LLC increased its position in Cooper Companies by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 4,906,463 shares of the medical device company’s stock valued at $449,907,000 after purchasing an additional 109,907 shares during the period. Finally, Victory Capital Management Inc. raised its holdings in Cooper Companies by 14.6% during the 4th quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company’s stock worth $415,985,000 after purchasing an additional 574,899 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.